Efficacy and safety of dual and triple antiplatelet therapies in East Asian patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized controlled trials - PubMe
6 hours ago
- #acute coronary syndrome
- #antiplatelet therapy
- #East Asian patients
- Systematic review and network meta-analysis (NMA) evaluates dual (DAPT) and triple antiplatelet therapy (TAPT) in East Asian ACS patients.
- 26 randomized controlled trials compared DAPT (P2Y12 inhibitor + aspirin) and TAPT (cilostazol + clopidogrel-based DAPT).
- Primary outcomes: major adverse cardiac events (MACEs) and major bleeding events.
- TAPT significantly reduced MACEs without increasing major bleeding events.
- Standard-dose potent P2Y12 inhibitor-based DAPT showed no MACE reduction but increased major bleeding.
- TAPT had the highest probability of reducing MACEs.
- DAPT with potent P2Y12 inhibitors and de-escalation minimized major bleeding events.
- Conclusion: TAPT offers efficacy without safety compromise; de-escalation balances DAPT efficacy and safety.